Children's Cancer Trial Team

Quote from Professor Kearns (Director CRCTU)  "We are delighted that our team can start work on a series of clinical trials which will hopefully bring real benefits to all children with cancer. While we have made great progress increasing the number of children who survive the disease it’s through trials of new treatments that we can help even more children survive."

On the 1st April 2010, 152 trials previously managed by the Children’s Cancer and Leukaemia Group (CCLG) moved to the CRCTU. The CRCTU has core funding from Cancer Research UK to run these trials and develop new children’s cancer trials. This core funding supports members of staff working in the newly formed Children’s Cancer Trials Team (CCTT) and other key CRCTU teams (Biostatistics, Quality Assurance/Monitoring, Programming and IT).

Transferred Trials

Nine trials transferred to the CRCTU open to recruitment:

  • Brain Stem Glioma Temozolamide
  • Euro-Ewings 99
  • EuroNet C1 Classic Hodgkins
  • High Risk Neuroblastoma
  • Interfant 06
  • LGG2
  • RMS 2005
  • SIOPEL 06
  • SIOP Wilms

Twelve trials transferred in follow-up, 15 transferred with analysis pending and 116 transferred closed to follow-up.

Due to the hard work, professionalism and commitment of the transfer team, both at the CCLG and at the CRCTU, this unprecedented transfer of trials was seamlessly achieved. A feat which has been recognised by the Chair of the NCRI Children’s Cancer & Leukaemia Clinical Study Group and the University of Birmingham who awarded the CRCTU members of the team a Birmingham University Award for Tremendous Achievement (BUAFTA) in January 2011

New Children’s Trials

Led by Professor Pamela Kearns (Senior Lecturer at the University of Birmingham and Paediatric Oncologist at Birmingham Children’s Hospital) the CCTT is working with investigators world wide to develop new trials for children with cancer and leukaemia .

The CCTT is split into two specialist groups who with other key staff in the CRCTU assist academic investigators in the design, development and subsequent management of trials:

  • The Early Phase Group who specialise in phase I trials, often in collaboration with the pharmaceutical industry, who work with the 9 specialist early phase children’s cancer treatment centres in the UK.
  • The Late Phase Group who specialise in phase II and III trials. Taking on the role as a (inter-) national coordinating centre and working with all 21 children’s cancer treatment centres across the UK.